结直肠癌患者结肠黏膜肿瘤坏死因子α诱导蛋白8样因子3的表达与意义

Expression and its clinical significance of tumor necrosis factor-α-induced protein-8 like-3 in colonic mucosaof patients with colon cancer

目的分析结直肠癌患者结肠黏膜肿瘤坏死因子α诱导蛋白8样因子3（TIPE3）的表达异常与临床病理特征之间的相关性。 方法采用实时荧光定量PCR检测58份结直肠癌组织及其癌旁组织中TIPE3 mRNA的表达情况，采用免疫组织化学SP法检测83份结直肠癌组织及其癌旁组织中TIPE3蛋白质的表达情况。采用非参数秩和检验和卡方检验进行统计学分析。 结果结直肠癌组织中TIPE3 mRNA相对表达量为0.719（0.104，0.887），低于癌旁组织的4.770（1.732，6.800），差异有统计学意义（Z＝－6.345，P〈0.05）。TIPE3 mRNA在不同性别、年龄和TNM分期的结直肠癌组织中表达差异均无统计学意义（P均〉0.05），有淋巴结转移组TIPE3 mRNA表达量低于无淋巴结转移组[0.113（0.061, 0.375）比0.489（0.327，0.956）；Z＝－3.815，P〈0.01]，术后生存期〈5年的患者TIPE3 mRNA表达量低于术后生存期≥5年患者组[0.104（0.049, 0.220）比0.482（0.266, 0.908）；Z＝－3.653，P〈0.01]，术后复发组患者TIPE3 mRNA表达量低于术后未复发组[0.188（0.091, 0.493）比0.409（0.233, 1.010）；Z＝－2.431，P＝0.015]。TIPE3 mRNA高表达组结直肠癌患者术后5年复发率低于TIPE3 mRNA低表达组[23.1%（6/26）比56.2%（18/32）]，差异有统计学意义（χ2＝6.508，P〈0.05）。结直肠癌组织中TIPE3蛋白质阳性表达率低于癌旁组织[44.6%（37/83）比68.7%（57/83）；χ2＝8.004，P〈0.05]，TIPE3的蛋白质表达在不同年龄、性别中差异均无统计学意义（P均〉0.05），Ⅱ期患者TIPE3蛋白质阳性表达率高于Ⅲ期患者[60.5%（23/38）比29.7%（11/37）]，差异有统计学意义（χ2＝7.174，P〈0.05），有淋巴结转移组TIPE3蛋白质阳性表达率低于无淋巴结转移组[28.2%（11/39）比59.1%（26/44）]，差异有统计学意义（χ2＝7.983，P＝0.005）。 结论TIPE3在结直肠癌组织中的表达较癌旁组织降低，且与结直肠癌的淋巴结转移、复发率和生存率均有关，TIPE3可能参与了结直肠癌的发生、发展和侵袭、转移。

ObjectiveTo detect the expression of tumor necrosis factor-α-induced protein-8 like-3 （TIPE3） in colonic mucosa of patients with colon cancer, and to analyze the correlation between its abnormal expression and clinicopathological features of patients with colon cancer. MethodsThe expression of TIPE3 mRNA in 58 cases of colon cancer and tumor-adjacent tissues was detected by real-time polymerase chain reaction （RT-PCR）. The expression of TIPE3 at protein level in 83 cases of colon cancer and tumor-adjacent tissues was determined by SP immunohistochemistry. Nonparametric rank-sum test and chi-square test were performed for statistical analysis. ResultsThe relative expression of TIPE3 mRNA in the colon cancer tissues was 0.719 （0.104 to 0.887）, which was lower than that of tumor-adjacent tissues （4.770, 1.732 to 6.800）, and the difference was statistically significant （Z=-6.345, P〈0.05）. There was no statistically significant difference in the expression of TIPE3 mRNA in colon cancer tissues between different gender, age and TNM stage （all P〉0.05）. The expression of TIPE3 mRNA in group of patients with lymph node metastasis （0.113, 0.061 to 0.375） was lower than group of patients without lymph node metastasis （0.489, 0.327 to 0.956; Z=-3.815, P〈0.01）. The expression of TIPE3 mRNA of patients survived less than five years after operation （0.104, 0.049 to 0.220） was lower than that of patients survived over five years （0.482, 0.266 to 0.908; Z=-3.653, P〈0.01）. The expression of TIPE3 mRNA of patients with recurrence after operation （0.188, 0.091 to 0.493） was lower than that of patients without recurrence （0.409, 0.233 to 1.010; Z=-2.431, P=0.015）. The recurrence rate of TIPE3 mRNA high expression group in five years after operation was lower than that of TIPE3 mRNA low expression group （23.1%, 6/26 vs 56.2%, 18/32）; and the difference was statistically significant （χ2=6.508, P〈0.05）. The expression of TIPE3 at protein level of colon cancer tissues （44.6%, 37/83） was lower than that of tumor-adjacent tissues （68.7%, 57/83; χ2=8.004, P〈0.05）. The expression of TIPE3 at protein level was not correlated with age and gender （both P〉0.05）. The positive expression rate of patients at stage Ⅱ was higher than that of patients at stage Ⅲ （60.5%, 23/38 vs 29.7%, 1/37）; and the difference was statistically significant （χ2=7.174, P〈0.05）. The positive expression rate of TIPE3 in group of patients with lymph node metastasis was lower than that of groups of patients without lymph node metastasis （28.2%, 11/39 vs 59.1%, 26/44）, and the difference was statistically significant （χ2=7.983, P=0.005）. ConclusionsThe expression of TIPE3 in colon cancer tissues is lower than that in tumor-adjacent tissues. Furthermore, it is correlated with lymph node metastasis, recurrence rate and survival rate. TIPE3 may be involved in the genesis, development, invasion and metastasis of colon cancer.